Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Gregory Michael Cote, M.D.

Co-Author

This page shows the publications co-authored by Gregory Cote and George Demetri.
Connection Strength

0.599
  1. A phase II multi-strata study of lurbinectedin as a single agent or in combination with conventional chemotherapy in metastatic and/or unresectable sarcomas. Eur J Cancer. 2020 02; 126:21-32.
    View in: PubMed
    Score: 0.224
  2. Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma. Cancer. 2015 Apr 15; 121(8):1223-30.
    View in: PubMed
    Score: 0.158
  3. Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy. BMC Cancer. 2014 Nov 05; 14:813.
    View in: PubMed
    Score: 0.157
  4. Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study. Lancet Oncol. 2020 11; 21(11):1423-1432.
    View in: PubMed
    Score: 0.059
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.